AI Article Synopsis
- Pharmacogenetic studies can uncover DNA variations that affect how individuals respond to medications, aiding in personalizing treatment plans.
- Effective study design and analysis require careful considerations, such as ensuring sufficient statistical power and addressing potential biases from different population groups.
- The Industry Pharmacogenomics Working Group is working toward establishing formal guidelines for conducting pharmacogenetic studies, which are presented in the paper.
Article Abstract
Pharmacogenetic association studies have the potential to identify variations in DNA sequence which impact drug response. Identifying these DNA variants can help to explain interindividual variability in drug response; this is the first step in personalizing dosing and treatment regimes to a patient's needs. There are many intricacies in the design and analysis of pharmacogenetic association studies, including having adequate power, selecting proper endpoints, detecting and correcting the effects of population stratification, modeling genetic and nongenetic covariates accurately, and validating the results. At this point there are no formal guidelines on the design and analysis of pharmacogenetic studies. The Industry Pharmacogenomics Working Group has initiated discussions regarding potential guidelines for pharmacogenetic study design and analyses (http://i-pwg.org) and the results from these discussions are presented in this paper.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/tpj.2008.11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Navigating Recent Changes in Dosing Information: Dynamics of FDA-Approved Monoclonal Antibodies in Post-Marketing Realities.
Clin Transl Sci
January 2025
College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea.
Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post-approval as new data emerge. This review evaluates post-marketing label changes in dosing information for FDA-approved mAbs from January 2015 to September 2024, with a focus on both initial and extended indications. We systematically analyzed dosing modifications, categorizing them into six predefined groups: Dose increases or decreases, inclusion of new patient populations by body weight or age, shifts from body weight-based dosing to fixed regimens, and adjustments in infusion rates.
View Article and Find Full Text PDFHow to facilitate the wider use of pharmacogenetic tests?
Therapie
December 2024
Centre de biologie et de recherche en santé, pharmacologie, toxicologie et pharmacovigilance, CHU de Limoges, 87042 Limoges, France.
4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table brought together a group of experts to take stock of the situation, reflecting on ways to facilitate the prescription of these tests and the dissemination of the results on a national scale.
View Article and Find Full Text PDFA foundation model of transcription across human cell types.
Nature
January 2025
Program of Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Transcriptional regulation, which involves a complex interplay between regulatory sequences and proteins, directs all biological processes. Computational models of transcription lack generalizability to accurately extrapolate to unseen cell types and conditions. Here we introduce GET (general expression transformer), an interpretable foundation model designed to uncover regulatory grammars across 213 human fetal and adult cell types.
View Article and Find Full Text PDFEnhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1.
Exp Biol Med (Maywood)
December 2024
Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
Pharmacogenomics (PGx) holds the promise of personalizing medical treatments based on individual genetic profiles, thereby enhancing drug efficacy and safety. However, the current landscape of PGx research is hindered by fragmented data sources, time-consuming manual data extraction processes, and the need for comprehensive and up-to-date information. This study aims to address these challenges by evaluating the ability of Large Language Models (LLMs), specifically Llama3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!